Menu Search
Equities

Maat Pharma SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4RD:FRA

Maat Pharma SA

Actions
  • Price (EUR)7.20
  • Today's Change0.10 / 1.41%
  • Shares traded5.75k
  • 1 Year change+3.15%
  • Beta0.3418
Data delayed at least 15 minutes, as of Feb 12 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Maat Pharma SA is a France-based company, which is engaged into research and development in biotechnology sector. The Company specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.

  • Revenue in EUR (TTM)3.92m
  • Net income in EUR-31.13m
  • Incorporated2014
  • Employees60.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.